These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 19824059)

  • 21. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
    Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
    Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].
    Wang Q; Zhong M; Lü YL; Yuan J; Wei LX
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):603-6. PubMed ID: 23157828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.
    Manne U; Gary BD; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
    Clin Cancer Res; 2001 Nov; 7(11):3495-503. PubMed ID: 11705868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas.
    Deb S; Xu H; Tuynman J; George J; Yan Y; Li J; Ward RL; Mortensen N; Hawkins NJ; McKay MJ; Ramsay RG; Fox SB
    Br J Cancer; 2014 Mar; 110(6):1606-13. PubMed ID: 24548858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
    Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
    Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
    Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
    Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
    Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
    Chang SC; Lin PC; Lin JK; Lin CH; Yang SH; Liang WY; Chen WS; Jiang JK
    Ann Surg Oncol; 2016 Mar; 23(3):849-55. PubMed ID: 26471487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
    Sameer AS; Chowdri NA; Syeed N; Banday MZ; Shah ZA; Siddiqi MA
    BMC Cancer; 2010 Jun; 10():300. PubMed ID: 20565773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.
    Kimura K; Nagasaka T; Hoshizima N; Sasamoto H; Notohara K; Takeda M; Kominami K; Iishii T; Tanaka N; Matsubara N
    J Int Med Res; 2007; 35(4):450-7. PubMed ID: 17697521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.
    Dinu D; Dobre M; Panaitescu E; Bîrlă R; Iosif C; Hoara P; Caragui A; Boeriu M; Constantinoiu S; Ardeleanu C
    J Med Life; 2014; 7(4):581-7. PubMed ID: 25713627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence.
    Kocián P; Šedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Špíšek R; Fialová A
    Hum Immunol; 2011 Nov; 72(11):1022-8. PubMed ID: 21884745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
    Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
    World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Difference between proximal and distal microsatellite-unstable sporadic colorectal cancers: analysis of clinicopathological and molecular features and prognoses.
    Kim YH; Min BH; Kim SJ; Choi HK; Kim KM; Chun HK; Lee H; Kim JY; Chang DK; Son HJ; Rhee PL; Rhee JC; Kim JJ
    Ann Surg Oncol; 2010 May; 17(5):1435-41. PubMed ID: 20049642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.